Human plasma derived hepatitis B vaccine: Kenyan experience

Area of Science:

• Hepatitis B research
• Vaccinology
• Immunology

Background:

• Hepatitis B virus (HBV) infection is a significant global health concern.
• Effective vaccination strategies are crucial for preventing HBV transmission and its chronic sequelae.
• Assessing vaccine efficacy and safety in diverse populations is essential for public health initiatives.

Purpose of the Study:

• To evaluate the immunogenicity and safety profile of Hepaccine B.
• To determine the proportion of vaccinees achieving protective antibody levels against Hepatitis B surface antigen (anti-HBs).

Main Methods:

• A cohort of 107 individuals (aged 0-10 years and 10+ years) received Hepaccine B vaccination.
• Antibody levels (anti-HBs) were measured one month after the third vaccine dose.
• Participants were recruited from Kenya Medical Research Institute (KEMRI) staff and their families in Nairobi.

Main Results:

• A high seroconversion rate was observed, with 97% of vaccinees developing anti-HBs antibodies.
• The vaccine elicited a robust immune response, indicating efficacy in generating protective immunity.
• Reported side effects were infrequent and mild, primarily consisting of local soreness at the injection site and headache.

Conclusions:

• Hepaccine B is an effective vaccine, demonstrating a strong capacity to induce protective immune responses against Hepatitis B.
• The vaccine exhibits a favorable safety profile with minimal adverse events, making it a potentially valuable tool for Hepatitis B prevention.
• The findings support the use of Hepaccine B in vaccination programs aimed at controlling Hepatitis B transmission.